Up-regulation of the receptor for advanced glycation end products in the skin biopsy specimens of patients with severe diabetic neuropathy

Journal of Clinical Neurology (Korea)

Volumn 10, Issue 4, 2014, Pages 334-341

  Park, Su Yeon ^a   Kim, Young A ^b   Hong, Yoon Ho ^b   Moon, Min Kyong ^b   Koo, Bo Kyeong ^b   Kim, Tae Wan ^b  

^a Korea Cancer Center Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Diabetes mellitus; Diabetic neuropathy; Receptor for advanced glycation end products

Indexed keywords

EID: 84908070235     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2014.10.4.334     Document Type: Article

References (41)

1. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012;11:521-534.
2. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:1790-1795.
3. Bril V. Treatments for diabetic neuropathy. J Peripher Nerv Syst 2012;17 Suppl 2:22-27.
4. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 2003;111:431-433.
5. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010;106:1319-1331.
6. Lauria G, Cornblath DR, Johansson O, McArthur JC, Mellgren SI, Nolano M, et al. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 2005;12:747-758.
7. England JD, Gronseth GS, Franklin G, Carter GT, Kinsella LJ, Cohen JA, et al. Practice Parameter: evaluation of distal symmetric polyneu-ropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009;72:177-184.
8. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2010;15:79-92.
9. Quattrini C, Tavakoli M, Jeziorska M, Kallinikos P, Tesfaye S, Finni-gan J, et al. Surrogate markers of small fber damage in human diabetic neuropathy. Diabetes 2007;56:2148-2154.
10. Shun CT, Chang YC, Wu HP, Hsieh SC, Lin WM, Lin YH, et al. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain 2004;127(Pt 7):1593-1605.
11. Polydefkis M, Hauer P, Sheth S, Sirdofsky M, Griffn JW, McArthur JC. The time course of epidermal nerve fbre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 2004;127(Pt 7):1606-1615.
12. Løseth S, Stålberg E, Jorde R, Mellgren SI. Early diabetic neuropathy: thermal thresholds and intraepidermal nerve fbre density in patients with normal nerve conduction studies. J Neurol 2008;255:1197-1202.
13. Wada R, Yagihashi S. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann N Y Acad Sci 2005;1043:598-604.
14. Yan SF, Barile GR, D’Agati V, Du Yan S, Ramasamy R, Schmidt AM. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 2007;7:146-153.
15. Misur I, Zarković K, Barada A, Batelja L, Milicević Z, Turk Z. Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy. Acta Diabetol 2004;41:158-166.
16. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001;280:E685-E694.
17. Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004;114: 1741-1751.
18. Haslbeck KM, Schleicher E, Bierhaus A, Nawroth P, Haslbeck M, Neundörfer B, et al. The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005;113:288-291.
19. Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM, Lastoskie C, et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 2007;148:548-558.
20. Toth C, Rong LL, Yang C, Martinez J, Song F, Ramji N, et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008;57:1002-1017.
21. Expert Committee on the Diagnosis and Classifcation of Diabetes Mellitus. Report of the expert committee on the diagnosis and classif-cation of diabetes mellitus. Diabetes Care 2003;26 Suppl 1:S5-S20.
22. Wilkinson CP, Ferris FLIII, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110: 1677-1682.
23. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17:1281-1289.
24. Berglund SR, Schwietert CW, Jones AA, Stern RL, Lehmann J, Goldberg Z. Optimized methodology for sequential extraction of RNA and protein from small human skin biopsies. J Invest Dermatol 2007;127: 349-353.
25. Fleige S, Pfaff MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 2006;27:126-139.
26. Chello M, Spadaccio C, Lusini M, Covino E, Blarzino C, De Marco F, et al. Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure. Diabetes Metab Res Rev 2009;25:420-426.
27. Ball TB, Plummer FA, HayGlass KT. Improved mRNA quantitation in LightCycler RT-PCR. Int Arch Allergy Immunol 2003;130:82-86.
28. Franke S, Sommer M, Rüster C, Bondeva T, Marticke J, Hofmann G, et al. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther 2009;11:R136.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-428.
30. Yuan JS, Reed A, Chen F, Stewart CNJr.. Statistical analysis of realtime PCR data. BMC Bioinformatics 2006;7:85.
31. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009;58:1634-1640.
32. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glyco-sylation end products of proteins. J Biol Chem 1992;267:14998-15004.
33. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, et al. RAGE modulates vascular infammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006;185:70-77.
34. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, et al. Receptor for advanced glycation end products (RAGE) def-ciency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461-2469.
35. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 1997;96:2262-2271.
36. Quehenberger P, Bierhaus A, Fasching P, Muellner C, Klevesath M, Hong M, et al. Endothelin 1 transcription is controlled by nuclear fac-tor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 2000;49:1561-1570.
37. Schmidt AM, Stern DM. RAGE: a new target for the prevention and treatment of the vascular and infammatory complications of diabetes. Trends Endocrinol Metab 2000;11:368-375.
38. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kane-da Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790.
39. Lin J, Bierhaus A, Bugert P, Dietrich N, Feng Y, Vo m Hagen F, et al. Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. Diabetologia 2006;49:1089-1096.
40. Hur J, Sullivan KA, Pande M, Hong Y, Sima AA, Jagadish HV, et al. The identifcation of gene expression profles associated with progression of human diabetic neuropathy. Brain 2011;134(Pt 11):3222-3235.
41. Haslbeck KM, Neundörfer B, Schlötzer-Schrehardtt U, Bierhaus A, Schleicher E, Pauli E, et al. Activation of the RAGE pathway: a general mechanism in the pathogenesis of polyneuropathies? Neurol Res 2007;29:103-110.